Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice

• Takahara, Ikuko

• Akazawa, Yuko

• Tabuchi, Maiko

• Matsuda, Katsuya

• Miyaaki, Hisamitsu

• Kido, Youko

• Kanda, Yasuko

• Taura, Naota

• Ohnita, Ken

• Takeshima, Fuminao

• Sakai, Yusuke

• Eguchi, Susumu

• Nakashima, Masahiro

• Nakao, Kazuhiko

• Salvatore Papa

  editor

抄録

Background and aims A high serum level of saturated free fatty acids (FFAs) is associated with the development of nonalcoholic fatty liver disease (NAFLD). X-box binding protein-1 (XBP-1) is activated by FFA treatment upon splicing. XBP-1 is a transcription factor induced by the endoplasmic reticulum (ER) stress sensor endoribonuclease inositol-requiring enzyme 1 alpha (IRE1α). However, the role of XBP-1 in NAFLD remains relatively unexplored. Toyocamycin was recently reported to attenuate the activation of XBP-1, possibly by inducing a conformational change in IRE1α. In this study, we examined the effect of toyocamycin on hepatocyte lipoapoptosis and steatosis. We also explored the effects of toyocamycin in a mouse model of NAFLD. Methods Huh-7 cells and isolated rat primary hepatocytes were treated with palmitic acid (PA), which is a saturated FFA, in the presence or absence of toyocamycin. In addition, male C57BL/6J mice were fed a diet rich in saturated fat, fructose, and cholesterol (FFC) for 4 months, after which the effect of toyocamycin was assessed. Results Toyocamycin attenuated FFA-induced steatosis. It also significantly reduced PA-induced hepatocyte lipoapoptosis. In addition, toyocamycin reduced the expression of cytosine-cytosine- adenosine-adenosine-thymidine enhancer-binding protein homologous protein (CHOP), which is a key player in ER stress-mediated apoptosis, as well as its downstream cell death modulator, death receptor 5. In the in vivo study, toyocamycin ameliorated the liver injury caused by FFC-induced NAFLD. It also reduced hepatic steatosis and the expression of lipogenic genes. Conclusions The data we obtained suggest that toyocamycin attenuates hepatocyte lipogenesis and ameliorates NAFLD in vivo and may therefore be beneficial in the treatment of NAFLD in humans.

PLOS ONE, 12(3), e0170591; 2017

収録刊行物

• PLOS ONE

  PLOS ONE 12 (3), e0170591-, 2017-03-09

  Public Library of Science

キーワード

• Multidisciplinary

詳細情報

• CRID: 1050568772240562432
• NII論文ID: 120006987538
• ISSN: 19326203
• DOI: 10.1371/journal.pone.0170591
• HANDLE: 10069/37479
• Web Site: https://nagasaki-u.repo.nii.ac.jp/records/2278
• Web Site: http://dx.plos.org/10.1371/journal.pone.0170591
• 本文言語コード: en
• 資料種別: journal article
• データソース種別:
  • IRDB
  • Crossref
  • CiNii Articles
  • KAKEN